Sanofi: Form 20-F for the period ended Dec 31, 2021
Filed with the SEC on Feb 23, 2022 and accepted by EDGAR at Feb 23, 2022, 13:00 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Cost of revenue | 12 months2021-01-01 to 2021-12-31 | EUR 12.26bn | ifrs-full:CostOfSales |
| Gross profit | 12 months2021-01-01 to 2021-12-31 | EUR 26.92bn | ifrs-full:GrossProfit |
| Operating income | 12 months2021-01-01 to 2021-12-31 | EUR 8.13bn | ifrs-full:ProfitLossFromOperatingActivities |
| Income tax | 12 months2021-01-01 to 2021-12-31 | EUR 1.56bn | ifrs-full:IncomeTaxExpenseContinuingOperations |
| Net income | 12 months2021-01-01 to 2021-12-31 | EUR 6.22bn | ifrs-full:ProfitLossAttributableToOwnersOfParent |
| Operating cash flow | 12 months2021-01-01 to 2021-12-31 | EUR 10.52bn | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Cash and equivalents | At period end2021-12-31 | EUR 10.10bn | ifrs-full:CashAndCashEquivalents |
| Total assets | At period end2021-12-31 | EUR 120.24bn | ifrs-full:Assets |
| Shareholders' equity | At period end2021-12-31 | EUR 68.68bn | ifrs-full:EquityAttributableToOwnersOfParent |
| Shares outstanding | At period end2021-12-31 | 1,263,560,695 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001121404-22-000007. Last ingested by Listed: Nov 5, 2026, 12:26 ET. Listed shows no prices and gives no investment advice.